Leadership Dr. Daniel Von Hoff The TD2 team is led by Dr. Daniel Von Hoff, Executive Vice President and Director of the Translational Drug Development Division at TGen, and a world-renowned expert in oncology drug development and clinical trial design. Daniel D. Von Hoff, M.D., is currently Physician-in-Chief and Senior Investigator at the Translational Genomics Research Institute (TGen) in Phoenix, Arizona and Clinical Professor of Medicine, University of Arizona Health Sciences Center. He is also Chief Scientific Officer for US Oncology and Chief Scientific Officer, Scottsdale Clinical Research Institute. Dr. Von Hoff's major interest is in the development of new anticancer agents, both in the clinic and in the laboratory. He and his colleagues were involved in the beginning of the development of many of the agents we now use routinely, including: mitoxantrone, fludarabine, paclitaxel, docetaxel, gemcitabine, CPT-11, nab-paclitaxel and many others. At present, he and his colleagues are concentrating on the development of molecularly targeted therapies. Dr. Von Hoff was appointed to President Bush's National Cancer Advisory Board in June 2004 – March 2010. Dr. Von Hoff is the past President of the American Association for Cancer Research, a Fellow of the American College of Physicians, and a member and past board member of the American Society of Clinical Oncology. He is a founder of ILEX™ Oncology, Inc. (acquired by Genzyme). He is founder and the Editor Emeritus of Investigational New Drugs – The Journal of New Anticancer Agents; and, Editor-in-Chief of Molecular Cancer Therapeutics. He is also proud to have been a mentor and teacher for multiple medical students, medical oncology fellows, graduate students, and post-doctoral fellows. MaryAnn Guerra President, TGen Accelerators, LLC. MaryAnn Guerra is President of TGen Accelerators, LLC and Chief Business Officer at TGen. Ms. Guerra's experience in developing and establishing the necessary relationships that enhance scientific programs and accelerate the transfer of technology from the lab into useful products and new business opportunities enables TGen to quickly advance its research agenda. Ms. Guerra has spent the past 20 years managing and operating successful and progressive health, science and technology businesses, as well as interacting with private, public and academic institutions. Ms. Guerra is an expert at business development and strategic planning initiatives that create organizations poised to deliver clinical and research outcomes. Her knowledge and experience in the field provides for effective leadership when responding to and creating specialized services that reflect the unique and distinct requirements needed across the health and technology arenas. Prior TGen, Ms. Guerra served as Executive Vice President of the Matthews Media Group, where she was responsible for developing and implementing a strategic business plan that expanded and enhanced services and extended relationships with the pharmaceutical and biotechnology industries. She directly managed the Commercial Division that focused on management, strategic partnerships, staffing, finance, proposal development and quality control on all projects. Ms. Guerra has also held various senior level positions at the National Institutes of Health, including: Deputy Director of Management at the NCI; Executive Officer of the National Heart, Lung, and Blood Institute; and Chief of the Technology Transfer and Intramural Management Branch at the National Institute of Allergy and Infectious Disease. As the Deputy Director for Management, National Cancer Institute (NCI), Ms. Guerra oversaw an organization with an annual budget in excess of $4 billion in appropriated funds and a staff of over 5,000. She directly supervised 525 employees with an operating budget of $127 million. Responsibilities included the overall management of NCI’s administrative operations, information systems, space and facilities, business development, and evaluation activities, which included interactions with other federal agencies, non-government organizations, and industry. Ms. Guerra holds an undergraduate degree from The Ohio State University and an MBA from George Washington University in Science, Innovation and Technology. Stephen Anthony, D.O. Chief Medical Officer. Dr. Stephen Anthony also serves as an Associate Clinical Investigator, TGen Clinical Research Services at Scottsdale Health Care. Dr. Anthony received his osteopathic medical degree from the Philadelphia College of Osteopathic Medicine. He then completed an Internal Medicine residency at Hahnemann University Hospital in Philadelphia, PA. From there he served on active duty for the USAF stationed at Holloman AFB. At Holloman he was assigned as a Flight Surgeon to the F117A (Stealth Fighter) squadron, which resulted in his deployment to Saudi Arabia, Kuwait and other Persian Gulf countries. Upon completion of this service he completed his fellowship in Hematology and Oncology at Dartmouth-Hitchcock Medical Center. For the past 9 years he has been in private practice mainly in Spokane, Washington where he successfully developed a Phase 1 program with Dr. Von Hoff and U.S. Oncology. At U.S. Oncology, Dr. Anthony was an active member of the clinical trials group and an active participant in developing early phase clinical trials. Stephen Gately, Ph.D. Chief Scientific Officer. Dr. Stephen Gately obtained his Ph.D. from McGill University in the Department of Neurology and Neurosurgery at the Montreal Neurological Institute and Hospital. Thereafter he joined the Department of Medicine, Division of Hematology/Oncology at Northwestern University Feinberg School of Medicine as Research Assistant Professor where his research focused on the identification and development of pharmacologic and endogenous inhibitors of angiogenesis. During this time, Dr. Gately served as a consultant to the Oncology Clinical Research Team at Searle/Monsanto (now Pfizer). In this position he was responsible for scientific and technical input on clinical trial designs to rapidly assess the utility of antiangiogenic compounds. Additional responsibilities included interacting with discovery scientists to understand drug mechanism of action to aid in the identification of potential biomarkers for early clinical proof of drug activity studies. He then joined the oncology-focused biopharmaceutical company NeoPharm where he served as Executive Director of Translational Medicine. In this position Dr. Gately had responsibility for the design and implementation of basic and clinical research studies to enhance the scientific understanding and positioning of existing products and development candidates. Dr. Gately then served as a consultant to Takeda Pharmaceuticals North America, Medical and Scientific Affairs group where he was responsible for the scientific integration of non-clinical, clinical and regulatory data on portfolio compounds for optimal commercial planning. In addition he was involved in the scientific due diligence for oncology new business development opportunities. Dr. Gately is currently Director of Nonclinical Development at TGen Drug Development Services (TD2), and an adjunct assistant professor of Medicine at the Northwestern University Feinberg School of Medicine. Debbie Snyder, M.B.A., R.T., C.L.S. (N.C.A.) Vice President, Operations. Debbie Snyder has over 15 years experience in oncology preclinical and clinical activities and is responsible for operational and business activities to support biopharmaceutical clients. Debbie has been with TGen for over three years building infrastructure, business models and partners to share in the translational mission of TGen. Ms. Snyder contributes a broad-ranging academic and professional grounding in immunology, hematology, microbiology and biochemistry with a Medical Laboratory Science background, coupled with an Executive Master of Business Administration degree from Simon Fraser University, Vancouver, Canada. Ms Snyder began her career working in the hospital laboratory, specializing in hematology at the BC Cancer Agency in Vancouver. In 1994, Ms. Snyder accepted a position with a start up biotechnology company, StemCell Technologies Inc. (STI) to establish a quality control department for developing and testing their products. Prior to joining TD2, Ms Snyder held a management position for a publicly traded start up medical device company, VSM MedTech Ltd, where she led cross-functional teams for manufacturing, engineering and sales, and was an integral team member to file, validate and obtain 510K & CE mark submissions. Ray Lamy Acting Senior Director, Regulatory Affairs.
		TD2 is an Affiliate of the Translational Genomics Research Institute